Immunogenicitet Omtrent 54% af de patienter, der blev behandlet med ustekinumab, udviklede antistoffer mod ustekinumab, sædvanligvis i lav titer.
Immunogenicity Approximately 5% of ustekinumab-treated patients developed antibodies to ustekinumab, which were generally low-titer.